Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
Torres, Antoni (Hospital Clínic i Provincial de Barcelona)
Bassetti, Matteo (Santa Maria della Misericordia University Hospital, Udine)
Welte, Tobias (Medizinische Hochschule Hannover)
Rivolo, Simone (Evidera, London)
Remak, Edit (Evidera, Budapest)
Peral, Carmen (Pfizer, Madrid)
Charbonneau, Claudie (Pfizer, Paris)
Hammond, Jennifer (Pfizer)
Ansari, Wajeeha (Pfizer, New York)
Grau, Santiago (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)

Data:	2020
Resum:	Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal. Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS). Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30. 6% vs. 26. 1%) while decreasing initial antibiotic failures (3. 8% vs. 7. 6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1. 2%) and significantly increased PDE (32. 1% vs. 24. 6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30. 6% vs. 14. 9%). Moxifloxacin and co-amoxiclav early response rate of 53. 63% and 54. 24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature. Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Journal of Medical Economics, Vol. 23 Núm. 2 (january 2020) , p. 148-155, ISSN 1941-837X

DOI: 10.1080/13696998.2019.1688819
PMID: 31686550

9 p, 1.7 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats